For research use only. Not for therapeutic Use.
WYE-354（Cat No.:I000313）is a potent and selective inhibitor of mTOR (mechanistic target of rapamycin), specifically targeting both mTORC1 and mTORC2 complexes. By inhibiting mTOR, WYE-354 effectively blocks downstream signaling pathways, including Akt, S6K, and 4E-BP1, which are crucial for cell growth, proliferation, and survival. Unlike rapamycin, WYE-354 provides comprehensive inhibition of mTOR, making it useful in studying the effects of mTOR inhibition on cancer cells and in metabolic disorders. It is widely used in cancer research to explore the role of mTOR signaling and its therapeutic targeting in tumor growth.
| Catalog Number | I000313 |
| CAS Number | 1062169-56-5 |
| Synonyms | methyl 4-[6-[4-(methoxycarbonylamino)phenyl]-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate |
| Molecular Formula | C24H29N7O5 |
| Purity | ≥95% |
| Target | Autophagy |
| Solubility | DMSO ≥96mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL |
| Storage | 3 years -20C powder |
| IC50 | 5 nM |
| IUPAC Name | methyl 4-[6-[4-(methoxycarbonylamino)phenyl]-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate |
| InChI | InChI=1S/C24H29N7O5/c1-34-23(32)26-17-5-3-16(4-6-17)20-27-21(29-11-13-36-14-12-29)19-15-25-31(22(19)28-20)18-7-9-30(10-8-18)24(33)35-2/h3-6,15,18H,7-14H2,1-2H3,(H,26,32) |
| InChIKey | IMXHGCRIEAKIBU-UHFFFAOYSA-N |
| SMILES | COC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=NN3C4CCN(CC4)C(=O)OC)C(=N2)N5CCOCC5 |
| Reference | </br>1:Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo. Wang L, Zhu YR, Wang S, Zhao S.Tumour Biol. 2016 Sep;37(9):11743-11752. Epub 2016 Mar 28. PMID: 27020593 </br>2:Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice. Weber H, Leal P, Stein S, Kunkel H, García P, Bizama C, Espinoza JA, Riquelme I, Nervi B, Araya JC, Grez M, Roa JC.Oncotarget. 2015 Oct 13;6(31):31877-88. doi: 10.18632/oncotarget.5047. PMID: 26397134 Free PMC Article |
